Rhythm Pharmaceuticals, Inc. (RYTM)

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

No competitor list for this company yet.

• 5/6/2026POSITIVE
  Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results

  Rhythm Pharmaceuticals (NASDAQ: RYTM) has seen analysts upgrade their Q1 forecasts following a strong earnings report. The company highlighted robust demand for its drug IMCIVREE, a key driver of the positive outlook. Furthermore, Rhythm Pharmaceuticals is advancing its strategic expansion plans, with potential launches anticipated in both European and Japanese markets. This dual approach of strong domestic performance and international growth initiatives positions the company favorably for sustained revenue increases and market share expansion, potentially leading to increased investor confidence and a higher stock valuation.

• 3/2/2026POSITIVE
  Rhythm Pharmaceuticals Discloses 18.8% BMI Drop In Rare Obesity Patients

  Rhythm Pharmaceuticals has disclosed compelling Phase 3 clinical trial data, showcasing an impressive 18.8% reduction in Body Mass Index (BMI) among patients suffering from rare forms of obesity. This positive development has fueled investor optimism, leading to a notable surge in the company's shares. The demonstrated efficacy of the drug positions Rhythm Pharmaceuticals favorably ahead of the crucial FDA decision, which is anticipated by March 20. Analysts suggest that regulatory approval could unlock a substantial market for treating these rare conditions, offering new hope for patients and significant growth opportunities for the company. Investors will closely watch the FDA's verdict, which will be pivotal for the stock's trajectory.

• 2/26/2026NEUTRAL
  Rhythm Pharma (RYTM) Earnings Call Transcript

  The market is keenly awaiting the earnings call transcript for Rhythm Pharmaceuticals (RYTM), but the specific content is currently unavailable. This lack of information prevents analysts from forming a precise judgment on the company's financial performance and future outlook. Investors will need to await the publication of details to assess the impact on revenues, costs, and management's guidance. The absence of concrete data makes it impossible to identify a clear trading signal, keeping the stock in a phase of uncertainty until further announcements.